Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
NCT ID: NCT00100906
Last Updated: 2013-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
18 participants
INTERVENTIONAL
2004-08-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase II trial is studying how well giving three different doses of tretinoin together with interleukin-2 works in treating patients with stage IV kidney cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Determine the ratio of dendritic cells (DC) to circulating immature cells (ImC) before and after treatment with 3 different doses of tretinoin in patients with stage IV renal cell cancer.
* Assess in vitro immune response assays to tetanus toxoid and influenza virus peptide before and after treatment with tretinoin and interleukin-2 in these patients.
Secondary
* Determine the frequency of treatment-related side effects in these patients.
* Determine clinical objective response and progression-free survival of patients treated with this regimen.
* Correlate DC:ImC ratio with clinical objective response in patients treated with this regimen.
* Correlate the extent of change of the DC:ImC ratio with tretinoin dose and tretinoin blood levels in these patients.
OUTLINE: This is a randomized, open-label study. Specimens are stratified according to patient prognostic factors, tumor bulk, and extent of dendritic cell to circulating immature cell ratio derangement. Patients are randomized to 1 of 3 tretinoin doses.
Patients are followed for up to 2 years.
PROJECTED ACCRUAL: A total of 27-36 patients (9-12 per treatment arm) will be accrued for this study within 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATRA Followed by IL-2 - Dose Level A
Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.
Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.
Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.
After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.
This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle.
IL-2
Immunotherapy with interleukin-2
ATRA
ATRA Followed by IL-2 - Dose Level B
Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.
Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.
Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.
After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.
This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle.
IL-2
Immunotherapy with interleukin-2
ATRA
ATRA Followed by IL-2 - Level C
Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.
Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.
Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.
After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.
This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle.
IL-2
Immunotherapy with interleukin-2
ATRA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IL-2
Immunotherapy with interleukin-2
ATRA
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed renal cell cancer
* Stage IV disease
* Histology with clear cell component
* Metastatic OR incompletely resected disease
* Non-measurable disease allowed
* Underwent complete or partial nephrectomy more than 90 days ago
* No unresected primary cancer
* No more than 2 of the following adverse factors:
* Hemoglobin \< 10.0 g/dL
* Corrected calcium \> upper limit of normal (ULN)
* Lactic dehydrogenase \> 1.5 times ULN
* Eastern Cooperative Oncology Group (ECOG) performance status 2
* Brain metastasis allowed provided more than 90 days of clinical and radiologic stability after the end of its active treatment
PATIENT CHARACTERISTICS:
Age
* Over 18
Performance status
* See Disease Characteristics
* ECOG 0-2
Life expectancy
* Not specified
Hematopoietic
* See Disease Characteristics
Hepatic
* See Disease Characteristics
* Serum glutamic oxaloacetic transaminase (SGOT) \< 3 times normal
* Bilirubin \< 2 times normal
Renal
* See Disease Characteristics
* Creatinine clearance \> 40 mL/min
Cardiovascular
* None of the following cardiovascular conditions within the past year:
* Uncontrolled hypertension
* Myocardial infarction
* Unstable angina
* New York Heart Association class II-IV congestive heart failure
* Serious cardiac arrhythmia requiring medication
* Class II-IV peripheral vascular disease within the past year
* Other clinically significant cardiovascular disease
Immunologic
* No history of immunodeficiency disease
* No HIV infection
* No ongoing serious infection
Other
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use two methods of effective contraception during and for 1 month (for women) or 6 months (for men) after study treatment
* Other prior malignancy allowed provided there is no evidence of active disease
* No other medical contraindication to tretinoin or interleukin-2
* No serious non-healing wound, ulcer, or bone fracture
PRIOR CONCURRENT THERAPY:
Biologic therapy
* At least 60 days since prior immunotherapy
Chemotherapy
* At least 60 days since prior cytotoxic chemotherapy
Endocrine therapy
* See Radiotherapy
* No prior corticosteroids at \> physiologic replacement doses for \> 3 days within the past 90 days
* Concurrent tamoxifen, toremifene, megestrol, or gonadotropin-releasing hormone agonists allowed
* Concurrent inhaled steroids allowed
Radiotherapy
* More than 7 days since prior external-beam radiotherapy
* No steroid requirement during radiotherapy
Surgery
* See Disease Characteristics
* At least 30 days since other prior debulking surgery
Other
* Prior adjuvant therapy for resected, synchronous stage IV disease allowed
* Prior adjuvant therapy allowed
* Study therapy is not to be used as adjuvant therapy for completely resected late (\> 1 year until identification) solitary site of disease metastasis or non-metastatic disease
* No prior participation in this clinical study
* At least 60 days since other prior anticancer drugs
* Concurrent seizure medication allowed
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
National Institutes of Health (NIH)
NIH
Chiron Corporation
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mayer Fishman, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
H. Lee Moffitt Cancer Center and Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006 Sep 15;66(18):9299-307. doi: 10.1158/0008-5472.CAN-06-1690.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA101324
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
CA84488
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
MCC-13920
Identifier Type: -
Identifier Source: org_study_id